At FLOUREN, our philosophy is anchored in 'the science of distinction'—bridging the gap between rigorous scientific discovery and premium wellness. Today, we are proud to share a professional review of a breakthrough clinical trial that expands the horizon of what next-generation probiotics can achieve.
The clinical review focuses on a landmark study evaluating the efficacy of heat-killed Akkermansia muciniphila (specifically the EB-AMDK19 strain) in patients suffering from persistent respiratory symptoms.
Behind the Science: The 12-Week Human Trial Published under the international study identifier DOI: 10.3390/nu16234113, this randomized, double-blind, placebo-controlled trial followed participants over a 12-week period to observe how advanced microbiome care influences systemic health. The findings are highly encouraging for the future of preventative care:
-
Targeted Cough & Breathlessness Relief: Participants who took the Akkermansia strain showed a statistically significant improvement in their Breathlessness, Cough, and Sputum Scale (BCSS) scores compared to the placebo group.
-
Safe Cellular-Level Stabilization: The study demonstrated that the heat-killed strain successfully stabilized the body's inflammatory markers, directly contributing to a clearer, calmer respiratory tract without any adverse side effects.
The FLOUREN Standard: Science-Backed Vitality This profound research confirms what we at FLOUREN have always believed: true vitality is interconnected. Nurturing your gut barrier with advanced, bio-technologically optimized Akkermansia formulas does far more than improve digestion—it acts as a foundational shield for your entire respiratory system.
Experience the power of a deeper, healthier breath, backed by undisputed clinical data.
💡 Research & Media Credits
-
Featured Clinical Review: Read the full analysis on Akkermansia muciniphila supplements may help with coughs.
-
Core Study Reference:
Nutrients 16(23), 4113l doi: 10.3390/nu16234113
"Efficacy of ETB-F01, Heat-Killed Akkermansia muciniphila Strain EB-AMDK19, in Patients with Respiratory Symptoms: A Multicenter Clinical Trial"
Authers: H.W. Lee et al.